Stuyvesant Capital Management’s VanEck Pharmaceutical ETF PPH Stock Holding History

Stuyvesant Capital Management’s Portfolio PPH Stock Details PPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-27,420	Closed	-$1.62M	–	33
2017 Q2	$1.62M	Buy	27,420 +600	+2%	+$33.9K	3.19%	16
2017 Q1	$1.48M	Buy	26,820 +3,000	+13%	+$163K	3.12%	15
2016 Q4	$1.25M	Sell	23,820 -3,540	-13%	-$189K	2.69%	17
2016 Q3	$1.57M	Hold	27,360	–	–	3.65%	15
2016 Q2	$1.6M	Buy	27,360 +125	+0.5%	+$7.29K	3.17%	17
2016 Q1	$1.57M	Sell	27,235 -1,015	-4%	-$60K	3.45%	15
2015 Q4	$1.84M	Hold	28,250	–	–	4.64%	12
2015 Q3	$1.78M	Sell	28,250 -3,150	-10%	-$221K	4.49%	11
2015 Q2	$2.22M	Buy	31,400 +900	+3%	+$64.8K	4.85%	10
2015 Q1	$2.14M	Buy	+30,500	New	+$2.07M	4.88%	8

Other funds holding PPH

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

SG Americas Securities New York $92.9B AUM 36.98% 1-Year Est. Return

RJA

Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BCI

Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return

PVH

Psagot Value Holdings Tel Aviv, Israel $11M AUM 32.09% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Stuyvesant Capital Management's PPH Position: Q3 2017 in Review

Stuyvesant Capital Management sold out of VanEck Pharmaceutical ETF (PPH) in Q3 2017, closing a stake of 27,420 shares — an estimated $1.62M sold.

Stuyvesant Capital Management first reported a position in PPH in Q1 2015 and held it in 10 quarters. The position peaked at $2.22M in Q2 2015. 48 funds tracked by Wall St. Rank hold PPH as of Q3 2017.

Stuyvesant Capital Management reported no remaining VanEck Pharmaceutical ETF position as of Q3 2017 after selling out during the quarter.
Stuyvesant Capital Management sold 27,420 VanEck Pharmaceutical ETF shares in Q3 2017, an estimated $1.62M.
Stuyvesant Capital Management first reported a position in VanEck Pharmaceutical ETF in Q1 2015 and held it in 10 quarters.
Stuyvesant Capital Management's VanEck Pharmaceutical ETF position peaked at $2.22M in Q2 2015.
48 funds tracked by Wall St. Rank held VanEck Pharmaceutical ETF as of Q3 2017.

Based on Stuyvesant Capital Management's 13F filing for Q3 2017, filed 7 Nov 2017.